[go: up one dir, main page]

BRPI0409895B8 - método de cultura de células derivadas de células per.c6 capazes de crescer em suspensão para aumentar o rendimento de produto das referidas células - Google Patents

método de cultura de células derivadas de células per.c6 capazes de crescer em suspensão para aumentar o rendimento de produto das referidas células

Info

Publication number
BRPI0409895B8
BRPI0409895B8 BRPI0409895A BRPI0409895A BRPI0409895B8 BR PI0409895 B8 BRPI0409895 B8 BR PI0409895B8 BR PI0409895 A BRPI0409895 A BR PI0409895A BR PI0409895 A BRPI0409895 A BR PI0409895A BR PI0409895 B8 BRPI0409895 B8 BR PI0409895B8
Authority
BR
Brazil
Prior art keywords
cells
per
growing
suspension
increase
Prior art date
Application number
BRPI0409895A
Other languages
English (en)
Inventor
Adam Yallop Christopher
Original Assignee
Crucell Holland Bv
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Janssen Vaccines & Prevention Bv filed Critical Crucell Holland Bv
Publication of BRPI0409895A publication Critical patent/BRPI0409895A/pt
Publication of BRPI0409895B1 publication Critical patent/BRPI0409895B1/pt
Publication of BRPI0409895B8 publication Critical patent/BRPI0409895B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"métodos para cultivar células imortalizadas pelas seqüências e1 de adenovírus e para produzir um produto em células imortalizadas pelas seqüências e1 de adenovírus, e, cultura de células imortalizadas pelas sequências e1 de adenovírus". a invenção proporciona processos para cultivar células derivadas de células embriônicas de retinoblasto por seqüências e1 de adenovírus, preferivelmente células per.c6^ tm^, para melhorar os rendimentos de produto de tais células. são proporcionadas estratégias de alimentação para tais células e culturas com densidades celulares muito altas, resultando em rendimentos elevados de produtos, tais como anticorpos recombinantes.
BRPI0409895A 2003-05-09 2004-05-06 método de cultura de células derivadas de células per.c6 capazes de crescer em suspensão para aumentar o rendimento de produto das referidas células BRPI0409895B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP0350155 2003-05-09
EP0350390 2003-09-01
EP0350940 2003-12-04
EP2004050061 2004-01-30
PCT/EP2004/050724 WO2004099396A1 (en) 2003-05-09 2004-05-06 Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom

Publications (3)

Publication Number Publication Date
BRPI0409895A BRPI0409895A (pt) 2006-05-23
BRPI0409895B1 BRPI0409895B1 (pt) 2018-09-18
BRPI0409895B8 true BRPI0409895B8 (pt) 2021-05-25

Family

ID=33437116

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409895A BRPI0409895B8 (pt) 2003-05-09 2004-05-06 método de cultura de células derivadas de células per.c6 capazes de crescer em suspensão para aumentar o rendimento de produto das referidas células

Country Status (15)

Country Link
US (4) US7291484B2 (pt)
EP (1) EP1623023B1 (pt)
JP (1) JP4865539B2 (pt)
KR (1) KR101183770B1 (pt)
CN (2) CN100383238C (pt)
AT (1) ATE414144T1 (pt)
AU (1) AU2004236440B2 (pt)
BR (1) BRPI0409895B8 (pt)
CA (1) CA2520891C (pt)
DE (1) DE602004017709D1 (pt)
DK (1) DK1623023T3 (pt)
EA (1) EA008670B1 (pt)
IL (2) IL171680A (pt)
NZ (1) NZ542585A (pt)
WO (1) WO2004099396A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
JP4480398B2 (ja) 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
ES2456015T3 (es) 2004-03-05 2014-04-21 Dsm Ip Assets B.V. Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante
ES2535230T3 (es) * 2005-01-05 2015-05-06 Chugai Seiyaku Kabushiki Kaisha Método de cultivo celular y utilización del mismo
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
CN104027359A (zh) 2006-01-23 2014-09-10 阿特西斯公司 无附加的免疫抑制治疗的mapc治疗法
EP1870450A1 (en) * 2006-06-21 2007-12-26 DSMIP Assets B.V. Process for the culturing of E1-immortalized HER cells
AU2011211462C1 (en) * 2006-07-14 2015-01-22 Dpx Holdings B.V. Improved process for the culturing of cells
WO2008006494A1 (en) 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Improved process for the culturing of cells
KR101248252B1 (ko) 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
DK2154244T3 (en) 2007-04-26 2017-06-12 Chugai Pharmaceutical Co Ltd CELL CULTIVATION PROCEDURE WHEN AN ACID-ENRICHED MEDIUM IS USED
EP3327132A3 (en) * 2007-08-09 2018-07-18 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
MX2011002328A (es) 2008-09-02 2011-05-19 Pluristem Ltd Celulas adherentes del tejido de placenta y su uso en terapia.
CN102439037B (zh) 2009-04-23 2015-01-07 克鲁塞尔荷兰公司 重组人α1-抗胰蛋白酶
RS53377B (sr) * 2009-07-16 2014-10-31 Crucell Holland B.V. Proizvodnja polio virusa u visokim titrima za proizvodnju vakcine
AU2010305765B2 (en) 2009-10-15 2015-07-02 Crucell Holland B.V. Method for the purification of adenovirus particles
PL2488635T3 (pl) 2009-10-15 2014-04-30 Crucell Holland Bv Proces do oczyszczania adenowirusa z hodowli o dużej gęstości komórek
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
CN107190034A (zh) 2010-10-05 2017-09-22 诺沃—诺迪斯克保健股份有限公司 生产蛋白质的方法
MY169935A (en) 2011-04-29 2019-06-18 Biocon Biologics India Ltd "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
CN102994547B (zh) * 2011-09-08 2015-05-13 哈药集团技术中心 重组人促红素-ctp融合蛋白生产工艺及应用
US9976163B2 (en) * 2012-10-03 2018-05-22 Kyowa Hakko Kirin Co., Ltd Method for preventing reduction of polypeptide by adding amino acid to culture solution
KR102245547B1 (ko) 2013-09-30 2021-04-28 얀센 백신스 앤드 프리벤션 비.브이. 고밀도의 미정제 세포 배양 수거물의 정화를 위한 방법
US10294460B2 (en) 2014-07-24 2019-05-21 Janssen Vaccines & Prevention B.V. Process for the purification of poliovirus from cell cultures
RU2672318C1 (ru) * 2017-09-19 2018-11-13 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Способ получения моноклональных антител терапевтического назначения с помощью непрерывного культивирования клеток сно
CN113924355B (zh) 2019-05-28 2024-04-02 上海药明生物技术有限公司 用于监测和自动控制灌流细胞培养的拉曼光谱集成灌流细胞培养系统
CN115369069B (zh) * 2022-08-22 2023-12-19 上海健士拜生物科技有限公司 293细胞补料培养基及其制备和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
GB8900483D0 (en) 1989-01-10 1989-03-08 Celltech Ltd Recombinant dna method
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
ES2100953T3 (es) 1991-08-01 1997-07-01 Fond Nat Transfusion Sanguine Expresion en lineas linfoblastoides humanas no tumorales con un vector integrante.
US5384249A (en) 1991-12-17 1995-01-24 Kyowa Hakko Kogyo Co., Ltd. α2→3 sialyltransferase
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US5733782A (en) 1993-10-25 1998-03-31 Creative Biomolecules, Inc. Methods and compositions for high protein production from non-native DNA
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5789247A (en) 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
US5610043A (en) 1994-04-28 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
IL122614A0 (en) * 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
EP0870839B1 (en) 1995-11-13 2006-05-10 Takara Bio Inc. Method for gene introduction into target cells by retrovirus
US5681597A (en) * 1996-02-06 1997-10-28 Liquid Container L.P. Vacuum conveyor picker for blow bottle container
US5856292A (en) 1996-04-08 1999-01-05 Colgate Palmolive Company Light duty liquid cleaning compositions
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
JP2001503266A (ja) 1996-10-25 2001-03-13 ジー．ディー．サール アンド カンパニー 環状に並べ替えたエリスロポイエチン受容体アゴニスト
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
JP2000509614A (ja) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスｅ１−相補性細胞系
CA2221819A1 (en) 1997-03-27 1998-09-27 Thomas A. Gigliatti Insect expression vectors
AU736334B2 (en) 1997-03-27 2001-07-26 University Of British Columbia, The Insect expression vectors
US5997128A (en) * 1997-05-30 1999-12-07 Hewlett-Packard Company Translational service station for imaging inkjet printheads
AU754619B2 (en) 1997-07-23 2002-11-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
CN1280309C (zh) 1997-12-03 2006-10-18 罗切诊断学有限公司 具有高比活的促红细胞生成素
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
NZ545478A (en) 1999-04-13 2008-04-30 Kenneth S Warren Inst Inc Modulation of excitable tissue function by peripherally administered erythropoietin
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
SI1161548T2 (sl) * 1999-04-15 2010-02-26 Crucell Holland Bv Priprava rekombinantnega proteina v humani celici z uporabo sekvenc, ki kodirajo adenovirusni E1 protein
WO2003048197A1 (en) 2001-12-07 2003-06-12 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
DE60032349T2 (de) 1999-04-26 2007-07-12 Genentech, Inc., South San Francisco Zellenzuchtverfahren für glycoproteine
US6215499B1 (en) * 1999-05-06 2001-04-10 Phillips Petroleum Company Method and apparatus for interactive curved surface seismic interpretation and visualization
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
EP1184458A1 (en) 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
EP1404813A4 (en) * 2001-06-13 2004-11-24 Genentech Inc METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
JP4371812B2 (ja) * 2001-09-28 2009-11-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ マイクロｒｎａ分子
JP4480398B2 (ja) 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
NZ533332A (en) 2001-12-17 2005-07-29 Crucell Holland B Efficient production of F(AB')2 fragments in mammalian cells
DK1504126T3 (da) * 2002-05-03 2014-06-10 Univ Duke Fremgangsmåde til regulering af genekspression
KR20060019501A (ko) 2002-07-01 2006-03-03 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 응답 세포, 조직 및 기관을 보호, 회복 및 향상시키기위한 재조합 조직 보호 사이토카인 및 이를 코딩하는 핵산
WO2004009779A2 (en) * 2002-07-19 2004-01-29 University Of South Carolina Compositions and methods for the modulation of gene expression in plants
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
US20050144669A1 (en) * 2003-07-01 2005-06-30 Whitehead Institute For Biomedical Research MicroRNAs in plants
US20050120415A1 (en) * 2003-10-09 2005-06-02 E.I. Du Pont De Nemours And Company Gene silencing
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
EP2081589B1 (en) 2006-11-16 2010-10-06 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants

Also Published As

Publication number Publication date
CN100383238C (zh) 2008-04-23
CN101328473B (zh) 2012-05-02
AU2004236440A1 (en) 2004-11-18
EA008670B1 (ru) 2007-06-29
KR101183770B1 (ko) 2012-09-17
JP4865539B2 (ja) 2012-02-01
EP1623023B1 (en) 2008-11-12
US20060240513A1 (en) 2006-10-26
NZ542585A (en) 2007-11-30
CN1784489A (zh) 2006-06-07
CA2520891C (en) 2014-07-08
WO2004099396A1 (en) 2004-11-18
BRPI0409895A (pt) 2006-05-23
US20070031932A1 (en) 2007-02-08
US20060121611A1 (en) 2006-06-08
EP1623023A1 (en) 2006-02-08
IL198861A (en) 2011-12-29
US8008043B2 (en) 2011-08-30
DK1623023T3 (da) 2009-03-02
KR20060003081A (ko) 2006-01-09
IL171680A (en) 2010-05-31
US7291484B2 (en) 2007-11-06
AU2004236440B2 (en) 2008-10-09
EA200501774A1 (ru) 2006-04-28
US7608431B2 (en) 2009-10-27
JP2006525800A (ja) 2006-11-16
DE602004017709D1 (de) 2008-12-24
BRPI0409895B1 (pt) 2018-09-18
ATE414144T1 (de) 2008-11-15
HK1080115A1 (en) 2006-04-21
US20100311160A1 (en) 2010-12-09
CN101328473A (zh) 2008-12-24
CA2520891A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
BRPI0409895B8 (pt) método de cultura de células derivadas de células per.c6 capazes de crescer em suspensão para aumentar o rendimento de produto das referidas células
ATE488600T1 (de) Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
TW200512297A (en) Mammalian cell culture processes for protein production
EA201270469A1 (ru) Способы культивирования клеток млекопитающих для получения белка
TW200736397A (en) Method of protein production using anti-senescence compounds
MX2009011363A (es) Metodo de produccion de proteinas utilizando compuestos anti-senectud.
WO2011134919A3 (en) Cho cells cultivation process 0
WO2002101019A3 (en) Methods of culturing animal cells and polypeptide production in animal cells
MX2007005132A (es) Medios libres de proteina animal para cultivo de celulas.
EP4148121A3 (en) Cell-controlled perfusion in continuous culture
NZ598677A (en) Production of proteins in glutamine-free cell culture media
MX2009011805A (es) Mejora de las concentraciones de polipeptido del factor viii en cultivos celulares.
WO2010089151A8 (en) Bioreactor for the cultivation of mammalian cells
WO2007002086A3 (en) Suspension culture of human embryonic stem cells
WO2004104190A3 (en) Methods and compositions for the production of adenoviral vectors
AR053947A1 (es) Celulas huespedes recombinantes y medios para la produccion de etanol
NO20072719L (no) Serumfritt cellekulturmedium for pattedyrceller
NO20064379L (no) Anvendelse av et serumfritt cellekulturmedium for produsjonen av IL-18BP i pattedyrceller
NZ599479A (en) Improved reverse genetics methods for virus rescue
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
BRPI0517942A (pt) meio de cultura de células isento de soro para células de mamìferos
Cai et al. Effects of iron electrovalence and species on growth of Haematococcus pluvialis and astaxanthin production
Fu et al. Study on biochemical quality of marine microalga Isochrysis galbana Parke through stoichiometry

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B15V Prolongation of time limit allowed

Free format text: REFERENTE A PETICAO NO 870180125497 DE 03.09.2018 - RECONHECIDO O OBSTACULO ADMINISTRATIVO, DE ACORDO COM O ARTIGO 221, 2O DA LPI 9279/96 E O ARTIGO 3O DA RESOLUCAO 178/2017, SEM CONCESSAO DE PRAZO ADICIONAL, EM VIRTUDE DO ATO JA TER SIDO CUMPRIDO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24D Patent annual fee: restoration after fee payment